Since it is known that YB-1 will be up-regulated as well as activated by phosphorylation and nuclear localization in patients who initially have been treated with radio-chemotherapy, the detected variability of YB-1 expression in different GBM specimen may be a result of different chemotherapy approaches and different cycles of chemotherapy the patients received. This evidence concerns the gene YBX1 and glioblastoma.